Why the study?
Since the 2017 identification of human acute and chronic hepatitis cases due to rat hepatitis E virus, 49 individuals have been confirmed worldwide, prompting an update on this emerging zoonosis.
Rat hepatitis E virus is an emerging zoonotic threat that requires specific diagnostic tools and primarily affects immunocompromised patients.
Answers are grounded in this paper and cite their sources.
May support ribavirin for chronic rHEV; leaves open need for controlled human trials.
Human infection with the hepatitis E virus (HEV) is the most common etiology of acute viral hepatitis globally. Estimates are of 20 million cases and 40,000 deaths per year. Researchers in Germany reported in 2009 a new 40–45 % genomic divergent hepevirus species in rats, named Rocahepevirus ratti . Human cases of both acute and chronic hepatitis due to rat HEV (rHEV) were first identified in Hong Kong in 2017. Since then, 49 individuals infected with rHEV have been confirmed worldwide. Herein, we provide an update on the virology, epidemiology, diagnosis, and clinical manifestations of this emerging zoonosis. Specific interventions, including vaccines and antivirals, as ribavirin, are being investigated. Ultimately holistic One Health approaches should be undertaken to confront this new health threat.
No takes yet. Share an insight, caveat, or question.
Soriano et al. (2026) conducted a review in Patients infected with rat hepatitis E virus (rHEV), including both immunocompetent and immunocompromised individuals worldwide (n=49). Ribavirin vs. None/placebo was evaluated on Viral elimination of chronic rat HEV infection.
Synapse has enriched 10 related papers. Consider them for comparative context: